6766.      Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra WO,Gollob KJ, Carvalho EM.Up-regulation of Th1-type responses in mucosal leishmaniasis patients.Infect Immun  2002 Dec;70(12):6734-40

6767.      Bosch RJ, Rodrigo AB, Sanchez P, de Galvez MV, Herrera E. Presence of Leishmania organisms in specific and non-specific skin lesions in HIV-infected individuals with visceral leishmaniasis. Int J Dermatol  2002 Oct;41(10):670-5

Pathogenesis:

6768.      Rodrigues EH, Felinto de Brito ME, Mendonca MG, Werkhauser RP, Coutinho EM, Souza WV, Militao de Albuquerque Mde F, Jardim ML, Abath FG. Evaluation of PCR for diagnosis of American cutaneous leishmaniasis in an area of endemicity in northeastern Brazil. J Clin Microbiol  2002 Oct;40(10):3572-6

6769.      Vilela RB, Bordin JO, Chiba AK, Castelo A, Barbosa MC. RBC-associated IgG in patients with visceral leishmaniasis (kala-azar): a prospective analysis. Transfusion  2002 Nov;42(11):1442-7

Therapy:

6770.      Del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E;  French Hospital Database on HIV Clinical Epidemiologic Group. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis  2002 Nov 1;186(9):1366-70

6771.      Jacobs S. An oral drug for leishmaniasis. N Engl J Med  2002 Nov 28;347(22):1737-8